164 related articles for article (PubMed ID: 27742794)
1. FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma.
Erbe AK; Wang W; Goldberg J; Gallenberger M; Kim K; Carmichael L; Hess D; Mendonca EA; Song Y; Hank JA; Cheng SC; Signoretti S; Atkins M; Carlson A; Mier JW; Panka DJ; McDermott DF; Sondel PM
Clin Cancer Res; 2017 May; 23(9):2159-2168. PubMed ID: 27742794
[No Abstract] [Full Text] [Related]
2. Genotyping Single Nucleotide Polymorphisms and Copy Number Variability of the FCGRs Expressed on NK Cells.
Erbe AK; Wang W; Gallenberger M; Hank JA; Sondel PM
Methods Mol Biol; 2016; 1441():43-56. PubMed ID: 27177655
[TBL] [Abstract][Full Text] [Related]
3. The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma.
McDermott DF; Cheng SC; Signoretti S; Margolin KA; Clark JI; Sosman JA; Dutcher JP; Logan TF; Curti BD; Ernstoff MS; Appleman L; Wong MK; Khushalani NI; Oleksowicz L; Vaishampayan UN; Mier JW; Panka DJ; Bhatt RS; Bailey AS; Leibovich BC; Kwon ED; Kabbinavar FF; Belldegrun AS; Figlin RA; Pantuck AJ; Regan MM; Atkins MB
Clin Cancer Res; 2015 Feb; 21(3):561-8. PubMed ID: 25424850
[TBL] [Abstract][Full Text] [Related]
4. Effect of FCGR polymorphism on the occurrence of late-onset neutropenia and flare-free survival in rheumatic patients treated with rituximab.
Ajeganova S; Tesfa D; Hägglund H; Fadeel B; Vedin I; Zignego AL; Palmblad J
Arthritis Res Ther; 2017 Mar; 19(1):44. PubMed ID: 28270182
[TBL] [Abstract][Full Text] [Related]
5. No association between FCGR2A and FCGR3A polymorphisms in Guillain-Barré Syndrome in a Brazilian population.
Dourado ME; Ferreira LC; Freire-Neto FP; Jeronimo SM
J Neuroimmunol; 2016 Sep; 298():160-4. PubMed ID: 27609290
[TBL] [Abstract][Full Text] [Related]
6. Fc-gamma receptor polymorphisms as predictive and prognostic factors in patients receiving oncolytic adenovirus treatment.
Hirvinen M; Heiskanen R; Oksanen M; Pesonen S; Liikanen I; Joensuu T; Kanerva A; Cerullo V; Hemminki A
J Transl Med; 2013 Aug; 11():193. PubMed ID: 23965133
[TBL] [Abstract][Full Text] [Related]
7. FCGR3A and FCGR2A Genotypes Differentially Impact Allograft Rejection and Patients' Survival After Lung Transplant.
Paul P; Pedini P; Lyonnet L; Di Cristofaro J; Loundou A; Pelardy M; Basire A; Dignat-George F; Chiaroni J; Thomas P; Reynaud-Gaubert M; Picard C
Front Immunol; 2019; 10():1208. PubMed ID: 31249568
[TBL] [Abstract][Full Text] [Related]
8. FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study.
Geva R; Vecchione L; Kalogeras KT; Jensen BV; Lenz HJ; Yoshino T; Paez D; Montagut C; Souglakos J; Cappuzzo F; Cervantes A; Frattini M; Fountzilas G; Johansen JS; Høgdall EV; Zhang W; Yang D; Yamazaki K; Nishina T; Papamichael D; Vincenzi B; Macarulla T; Loupakis F; De Schutter J; Spindler KL; Pfeiffer P; Ciardiello F; Piessevaux H; Tejpar S
Gut; 2015 Jun; 64(6):921-8. PubMed ID: 25011934
[TBL] [Abstract][Full Text] [Related]
9. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab.
Zhang W; Gordon M; Schultheis AM; Yang DY; Nagashima F; Azuma M; Chang HM; Borucka E; Lurje G; Sherrod AE; Iqbal S; Groshen S; Lenz HJ
J Clin Oncol; 2007 Aug; 25(24):3712-8. PubMed ID: 17704420
[TBL] [Abstract][Full Text] [Related]
10. Association analysis of copy numbers of FC-gamma receptor genes for rheumatoid arthritis and other immune-mediated phenotypes.
Franke L; el Bannoudi H; Jansen DT; Kok K; Trynka G; Diogo D; Swertz M; Fransen K; Knevel R; Gutierrez-Achury J; Ärlestig L; Greenberg JD; Kremer J; Pappas DA; Kanterakis A; Weersma RK; van der Helm-van Mil AH; Guryev V; Rantapää-Dahlqvist S; Gregersen PK; Plenge RM; Wijmenga C; Huizinga TW; Ioan-Facsinay A; Toes RE; Zhernakova A
Eur J Hum Genet; 2016 Feb; 24(2):263-70. PubMed ID: 25966632
[TBL] [Abstract][Full Text] [Related]
11. Impact of Fc gamma-receptor polymorphisms on the response to rituximab treatment in children and adolescents with mature B cell lymphoma/leukemia.
Burkhardt B; Yavuz D; Zimmermann M; Schieferstein J; Kabickova E; Attarbaschi A; Lisfeld J; Reiter A; Makarova O; Worch J; Bonn BR; Damm-Welk C
Ann Hematol; 2016 Sep; 95(9):1503-12. PubMed ID: 27376362
[TBL] [Abstract][Full Text] [Related]
12. Fc gamma receptor 3A polymorphism and risk for HIV-associated cryptococcal disease.
Rohatgi S; Gohil S; Kuniholm MH; Schultz H; Dufaud C; Armour KL; Badri S; Mailliard RB; Pirofski LA
mBio; 2013 Aug; 4(5):e00573-13. PubMed ID: 23982074
[TBL] [Abstract][Full Text] [Related]
13.
Moraru M; Perez-Portilla A; Al-Akioui Sanz K; Blazquez-Moreno A; Arnaiz-Villena A; Reyburn HT; Vilches C
Front Immunol; 2021; 12():615645. PubMed ID: 34108956
[TBL] [Abstract][Full Text] [Related]
14. FCGR2A and FCGR3A Genotypes Correlate with Farletuzumab Response in Patients with First-Relapsed Ovarian Cancer Exhibiting Low CA125.
Wang W; Somers EB; Ross EN; Kline JB; O'Shannessy DJ; Schweizer C; Weil S; Grasso L; Nicolaides NC
Cytogenet Genome Res; 2017; 152(4):169-179. PubMed ID: 29041009
[TBL] [Abstract][Full Text] [Related]
15. High-dose interleukin2 - a 10-year single-site experience in the treatment of metastatic renal cell carcinoma: careful selection of patients gives an excellent outcome.
Chow S; Galvis V; Pillai M; Leach R; Keene E; Spencer-Shaw A; Shablak A; Shanks J; Liptrot T; Thistlethwaite F; Hawkins RE
J Immunother Cancer; 2016; 4():67. PubMed ID: 27777776
[TBL] [Abstract][Full Text] [Related]
16. Copy number variation at the FCGR locus includes FCGR3A, FCGR2C and FCGR3B but not FCGR2A and FCGR2B.
Breunis WB; van Mirre E; Geissler J; Laddach N; Wolbink G; van der Schoot E; de Haas M; de Boer M; Roos D; Kuijpers TW
Hum Mutat; 2009 May; 30(5):E640-50. PubMed ID: 19309690
[TBL] [Abstract][Full Text] [Related]
17. FCGR2A, FCGR3A polymorphisms and therapeutic efficacy of anti-EGFR monoclonal antibody in metastatic colorectal cancer.
Ying HQ; Wang F; Chen XL; He BS; Pan YQ; Jie C; Liu X; Cao WJ; Peng HX; Lin K; Wang SK
Oncotarget; 2015 Sep; 6(29):28071-83. PubMed ID: 26363448
[TBL] [Abstract][Full Text] [Related]
18. Impact of Human FcγR Gene Polymorphisms on IgG-Triggered Cytokine Release: Critical Importance of Cell Assay Format.
Hussain K; Hargreaves CE; Rowley TF; Sopp JM; Latham KV; Bhatta P; Sherington J; Cutler RM; Humphreys DP; Glennie MJ; Strefford JC; Cragg MS
Front Immunol; 2019; 10():390. PubMed ID: 30899264
[TBL] [Abstract][Full Text] [Related]
19. FcGR genetic polymorphisms and the response to adalimumab in patients with rheumatoid arthritis.
Dávila-Fajardo CL; van der Straaten T; Baak-Pablo R; Medarde Caballero C; Cabeza Barrera J; Huizinga TW; Guchelaar HJ; Swen JJ
Pharmacogenomics; 2015; 16(4):373-81. PubMed ID: 25823785
[TBL] [Abstract][Full Text] [Related]
20. Association of FCGR2A and FCGR2A-FCGR3A haplotypes with susceptibility to giant cell arteritis.
Morgan AW; Robinson JI; Barrett JH; Martin J; Walker A; Babbage SJ; Ollier WE; Gonzalez-Gay MA; Isaacs JD
Arthritis Res Ther; 2006; 8(4):R109. PubMed ID: 16846526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
